The Achievement of Long-Term CRPC Control in a Patient with Enzalutamide-Induced Nausea and Fatigue after Overcoming the Adverse Events with a Temporary Drug Holiday
While the overall survival of patients with castration-resistant prostate cancer (CRPC) has been prolonged by enzalutamide, a considerable number of patients suffer from enzalutamide-induced nausea and fatigue. An 86-year-old male patient who started enzalutamide (160 mg) for CRPC treatment, experie...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2019-07-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/501849 |
| id |
doaj-19ab5700311b4aa2a92410d04757d243 |
|---|---|
| record_format |
Article |
| spelling |
doaj-19ab5700311b4aa2a92410d04757d2432020-11-24T20:40:21ZengKarger PublishersCase Reports in Oncology1662-65752019-07-0112256857210.1159/000501849501849The Achievement of Long-Term CRPC Control in a Patient with Enzalutamide-Induced Nausea and Fatigue after Overcoming the Adverse Events with a Temporary Drug HolidayTakashi KawaharaYasuhide MiyoshiMasahiro YaoHiroji UemuraWhile the overall survival of patients with castration-resistant prostate cancer (CRPC) has been prolonged by enzalutamide, a considerable number of patients suffer from enzalutamide-induced nausea and fatigue. An 86-year-old male patient who started enzalutamide (160 mg) for CRPC treatment, experienced nausea and vomiting approximately 2 weeks after the start of treatment. Enzalutamide treatment was stopped for two weeks, then restarted enzalutamide at a half-dose (80 mg); the dose was then increased to 120 mg. He remained free from any adverse events and showed good CRPC control for 53 months. We herein report the case of a patient with enzalutamide-induced nausea and vomiting, whose symptoms were overcome and in whom long-term CRPC control was achieved following a temporary drug holiday.https://www.karger.com/Article/FullText/501849EnzalutamidXtandiDrug holiday |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Takashi Kawahara Yasuhide Miyoshi Masahiro Yao Hiroji Uemura |
| spellingShingle |
Takashi Kawahara Yasuhide Miyoshi Masahiro Yao Hiroji Uemura The Achievement of Long-Term CRPC Control in a Patient with Enzalutamide-Induced Nausea and Fatigue after Overcoming the Adverse Events with a Temporary Drug Holiday Case Reports in Oncology Enzalutamid Xtandi Drug holiday |
| author_facet |
Takashi Kawahara Yasuhide Miyoshi Masahiro Yao Hiroji Uemura |
| author_sort |
Takashi Kawahara |
| title |
The Achievement of Long-Term CRPC Control in a Patient with Enzalutamide-Induced Nausea and Fatigue after Overcoming the Adverse Events with a Temporary Drug Holiday |
| title_short |
The Achievement of Long-Term CRPC Control in a Patient with Enzalutamide-Induced Nausea and Fatigue after Overcoming the Adverse Events with a Temporary Drug Holiday |
| title_full |
The Achievement of Long-Term CRPC Control in a Patient with Enzalutamide-Induced Nausea and Fatigue after Overcoming the Adverse Events with a Temporary Drug Holiday |
| title_fullStr |
The Achievement of Long-Term CRPC Control in a Patient with Enzalutamide-Induced Nausea and Fatigue after Overcoming the Adverse Events with a Temporary Drug Holiday |
| title_full_unstemmed |
The Achievement of Long-Term CRPC Control in a Patient with Enzalutamide-Induced Nausea and Fatigue after Overcoming the Adverse Events with a Temporary Drug Holiday |
| title_sort |
achievement of long-term crpc control in a patient with enzalutamide-induced nausea and fatigue after overcoming the adverse events with a temporary drug holiday |
| publisher |
Karger Publishers |
| series |
Case Reports in Oncology |
| issn |
1662-6575 |
| publishDate |
2019-07-01 |
| description |
While the overall survival of patients with castration-resistant prostate cancer (CRPC) has been prolonged by enzalutamide, a considerable number of patients suffer from enzalutamide-induced nausea and fatigue. An 86-year-old male patient who started enzalutamide (160 mg) for CRPC treatment, experienced nausea and vomiting approximately 2 weeks after the start of treatment. Enzalutamide treatment was stopped for two weeks, then restarted enzalutamide at a half-dose (80 mg); the dose was then increased to 120 mg. He remained free from any adverse events and showed good CRPC control for 53 months. We herein report the case of a patient with enzalutamide-induced nausea and vomiting, whose symptoms were overcome and in whom long-term CRPC control was achieved following a temporary drug holiday. |
| topic |
Enzalutamid Xtandi Drug holiday |
| url |
https://www.karger.com/Article/FullText/501849 |
| work_keys_str_mv |
AT takashikawahara theachievementoflongtermcrpccontrolinapatientwithenzalutamideinducednauseaandfatigueafterovercomingtheadverseeventswithatemporarydrugholiday AT yasuhidemiyoshi theachievementoflongtermcrpccontrolinapatientwithenzalutamideinducednauseaandfatigueafterovercomingtheadverseeventswithatemporarydrugholiday AT masahiroyao theachievementoflongtermcrpccontrolinapatientwithenzalutamideinducednauseaandfatigueafterovercomingtheadverseeventswithatemporarydrugholiday AT hirojiuemura theachievementoflongtermcrpccontrolinapatientwithenzalutamideinducednauseaandfatigueafterovercomingtheadverseeventswithatemporarydrugholiday AT takashikawahara achievementoflongtermcrpccontrolinapatientwithenzalutamideinducednauseaandfatigueafterovercomingtheadverseeventswithatemporarydrugholiday AT yasuhidemiyoshi achievementoflongtermcrpccontrolinapatientwithenzalutamideinducednauseaandfatigueafterovercomingtheadverseeventswithatemporarydrugholiday AT masahiroyao achievementoflongtermcrpccontrolinapatientwithenzalutamideinducednauseaandfatigueafterovercomingtheadverseeventswithatemporarydrugholiday AT hirojiuemura achievementoflongtermcrpccontrolinapatientwithenzalutamideinducednauseaandfatigueafterovercomingtheadverseeventswithatemporarydrugholiday |
| _version_ |
1716827260738076672 |